Montaro^™

Indication:
Montaro^™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise o improve glycemic control in adults with type-2 diabetes mellitus. It is also indicated for overweight or obesity with or without diabetes.

Dosage & Administration:
Montaro is injected subcutaneously and can be taken at any time of the day, regardless of the timing of meals.
Starting dose: Start Montaro with 2.5 mg once weekly for 4 weeks
Maintenance dose: After 4 weeks increase the dose to 5 mg once weekly
For additional glycemic control: If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose

Preparation:
Montaro^™ 2.5 mg Injection: Each box contains 1 pre-filled syringe of 0.5 mL solution of Tirzepatide INN 2.5 mg lnjection in Alu-PVC blister pack.
Montaro^™ 5 mg injection: Each box contains 1 pre-filled syringe of 0.5 mL solution of Tirzepatide 5 mg lnjection in Alu-PVC blister pack.